Treatment of Relapsed B/T-cell Mixed Phenotype Acute Leukemia With Blinatumomab

Here, we describe the treatment of a patient with relapsed/refractory B/T mixed phenotype acute leukemia (MPAL) using blinatumomab monotherapy, the first bispecific T cell engager (BiTE) approved by the FDA for relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). A 64-year-old man with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdo, Yasmeen, Gibson, Geoffrey D, Jain, Sarika P, Milner, Carter P, Hilal, Talal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356569/
https://www.ncbi.nlm.nih.gov/pubmed/37485162
http://dx.doi.org/10.7759/cureus.40661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356569/
https://www.ncbi.nlm.nih.gov/pubmed/37485162
http://dx.doi.org/10.7759/cureus.40661

Ejemplares similares